management of relapse after car-t
Published 2 years ago • 241 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
2:11
pirtobrutinib as a bridge to car-t therapy in b-cell malignancies
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:13
transplant and car-t for relapsed mcl
-
2:30
car-t as a new standard of care in lymphoma
-
2:25
the future of car-t for the treatment of lymphoma
-
1:43
r series auto case upload and auto case deletion v17.08
-
3:14
car t-cell therapy explained (manufacturing process & how it works)
-
7:46
immune effector cell associated neurotoxicity syndrome icans
-
1:43
management of car-t related side effects
-
1:36
the use of outpatient cilta-cel in the treatment of multiple myeloma
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
0:55
managing crs after car-t therapy
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:23
management of crs and icans after car-t therapy for all
-
3:07
the role of bridging and timing in car-t
-
1:55
unmet needs in dlbcl: frontline therapy, car-t optimization, and clinical trial inclusion
-
3:33
an overview of the car t-cell therapy story
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
10:22
cd19 car-t in lymphoma patients in the uk
-
3:21
safety management of car-t cell therapy in dlbcl
-
3:21
practical considerations for car-t therapy in lymphoma